On June 30, 2020, Armistice Capital LLC announced that in connection with the announced proposed merger of Tetraphase Pharmaceuticals, Inc. and La Jolla Pharmaceutical Company, on June 24, 2020, Armistice Capital Master Fund Ltd. entered into a support agreement with: (i) La Jolla Pharmaceutical; and (ii) TTP Merger Sub, Inc. La Jolla Pharmaceutical stated that pursuant to the support agreement, Armistice Capital Master Fund agreed to, among other things, (i) vote against other proposals to acquire the Company, and (ii) subject to certain exceptions, to tender its shares in connection with TTP Merger Sub’s cash tender offer, on behalf of La Jolla Pharmaceutical, to acquire all of the Company’s shares. Armistice Capital stated that the support agreement also sets forth terms relating to the treatment of warrants of the Company currently held by Armistice Capital Master Fund upon consummation of the Merger.